Surgery results in greater improvement in weight loss outcomes and weight associated comorbidities compared with non-surgical interventions , regardless of the type of procedures used .
When compared with each other , certain procedures result ed in greater weight loss and improvements in comorbidities than others .
Outcomes were similar between RYGB and sleeve gastrectomy , and both of these procedures had better outcomes than adjustable gastric b and ing .
For people with very high BMI , biliopancreatic diversion with duodenal switch result ed in greater weight loss than RYGB .
Isolated sleeve gastrectomy led to better weight-loss outcomes than adjustable gastric b and ing after three years follow-up .
BACKGROUND Bariatric ( weight loss ) surgery for obesity is considered when other treatments have failed .
The effects of the available bariatric procedures compared with medical management and with each other are uncertain .
This is an up date of a Cochrane review first published in 2003 and most recently up date d in 2009 .
OBJECTIVES To assess the effects of bariatric surgery for overweight and obesity , including the control of comorbidities .
Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding.
The goal of this study was to underst and the mechanisms of greater weight loss by  gastric bypass ( GBP )  compared to gastric b and ing ( GB ) surgery .  Obese weight- and age-matched subjects were studied before ( T0 ) , after a 12 kg weight loss ( T1 ) by GBP ( n = 11 ) or GB ( n = 9 ) , and at 1 year after surgery ( T2 ) . peptide YY(3 - 36 ) ( PYY(3 - 36 ) ) , ghrelin , glucagon-like peptide-1 ( GLP-1 ) , leptin , and amylin were measured after an oral glucose challenge . At T1 , glucose-stimulated GLP-1 and PYY levels increased significantly after GBP but not GB . Ghrelin levels did not change significantly after either surgery . In spite of equivalent weight loss , leptin and amylin decreased after GBP , but not after GB . At T2 , weight loss was greater after GBP than GB ( P = 0.003 ) . GLP-1 , PYY , and amylin levels did not significantly change from T1 to T2 ; leptin levels continued to decrease after GBP , but not after GB at T2 . Surprisingly , ghrelin area under the curve ( AUC ) increased 1 year after GBP ( P = 0.03 ) . These data show that , at equivalent weight loss , favorable GLP-1 and PYY changes occur after GBP , but not GB , and could explain the difference in weight loss at 1 year . Mechanisms other than weight loss may explain changes of leptin and amylin after GBP
Surgery results in greater improvement in weight loss outcomes and weight associated comorbidities compared with non-surgical interventions , regardless of the type of procedures used .
When compared with each other , certain procedures result ed in greater weight loss and improvements in comorbidities than others .
Outcomes were similar between RYGB and sleeve gastrectomy , and both of these procedures had better outcomes than adjustable gastric b and ing .
For people with very high BMI , biliopancreatic diversion with duodenal switch result ed in greater weight loss than RYGB .
Isolated sleeve gastrectomy led to better weight-loss outcomes than adjustable gastric b and ing after three years follow-up .
BACKGROUND Bariatric ( weight loss ) surgery for obesity is considered when other treatments have failed .
The effects of the available bariatric procedures compared with medical management and with each other are uncertain .
This is an up date of a Cochrane review first published in 2003 and most recently up date d in 2009 .
OBJECTIVES To assess the effects of bariatric surgery for overweight and obesity , including the control of comorbidities .